<DOC>
	<DOCNO>NCT00862472</DOCNO>
	<brief_summary>The purpose study demonstrate IOP-lowering efficacy DuoTrav APS , dose once-daily morning , non-inferior DuoTrav , dose once-daily morning .</brief_summary>
	<brief_title>Safety Efficacy Study DuoTrav APS Versus DuoTrav</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Cloprostenol</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Patients openangle glaucoma ocular hypertension would benefit fixed combination medication , opinion investigator currently stable treatment IOPlowering medication VA worse 0.60 additional clinically relevant ocular systemic condition may exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>open-angle glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
	<keyword>open-angle glaucoma ( without pseudoexfoliation pigment dispersion component )</keyword>
</DOC>